Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747949 · ClinicalTrials.gov registry record · Phase 3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
A Phase 3 study of Sjögren's Syndrome, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 844
- Enrollment target
- 20
- Study locations
NCT06747949 is a Phase 3 study of Sjögren's Syndrome that is actively recruiting participants, run by Amgen. The registered enrollment target is 844 participants, above the 297-participant average among 4 other Sjögren's Syndrome trials with a reported enrollment target (184% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06747949, a Phase 3 study of Sjögren's Syndrome, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 844 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Conditions Studied
Interventions
- DRUG Dazodalibep
Study Locations (20)
Arizona
- Arizona Arthritis & Rheumatology Associates - Avondale - Avondale
- Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln - Flagstaff
- Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St - Gilbert
- Arizona Arthritis and Rheumatology Associates - Glendale - 5681 W Beverly Ln - Glendale
- Arizona Arthritis and Rheumatology Associates - Tucson - 2001 W Orange Grove Rd - Tucson
Florida
- Bradenton Research Center Inc - Bradenton
- Clinical Research of West Florida Inc - Clearwater - Clearwater
- BayCare Medical Group Primary Care and Rheumatology - Tampa - Tampa
North Carolina
- Arthritis and Osteoporosis Consultants of The Carolinas - Charlotte - 1918 Randolph Rd - Charlotte
- Duke Early Phase Clinical Research Unit - PPDS - Durham
- Onsite Clinical Solutions, LLC - Salisbury - Salisbury
California
- Samy Metyas MD Inc - Covina
- UCSD Altman Clinical and Translational Research Institute Building - La Jolla
Ohio
- Arthritis & Osteoporosis Center of Southwest Ohio - Miamisburg - Miamisburg
- University of Toledo Medical Center - Toledo
Colorado
- Tekton Research, LLC - 2121 E Harmony Rd - PPDS - Fort Collins
Massachusetts
- Tufts University School of Dental Medicine - Boston
Michigan
- Shores Rheumatology - Saint Clair Shores
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 844 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2029-12-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06747949
The ClinicalTrials.gov registry entry for NCT06747949 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 844 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 297-participant average among 4 other Sjögren's Syndrome trials with a reported enrollment target (184% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjögren's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Dazodalibep is the first listed.
NCT06747949 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Arizona, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06747949 about?
NCT06747949 is a clinical study titled "A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)". The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
What is the current status of trial NCT06747949?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 844 participants. The study started on 2025-02-25. Estimated completion is 2029-12-11.
What conditions does trial NCT06747949 study?
This clinical trial studies the following conditions: Sjögren's Syndrome.
What interventions are being tested in trial NCT06747949?
The interventions under investigation include: Dazodalibep (DRUG).
Who is sponsoring clinical trial NCT06747949?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747949 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjögren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
RECRUITING · Phase 1
-
A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
COMPLETED
-
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.